A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
Phase 4
Completed
- Conditions
- Efficacy and Safety
- Interventions
- Drug: Huazhi Rougan granule
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 2007
- Registration Number
- NCT06202456
- Locations
- 🇨🇳
Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
A Phase IV Study of Huazhi Rougan Granule
Phase 4
Completed
- Conditions
- A Phase IV Trial to Investigate the Efficacy and Safety of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
- Interventions
- Drug: Huazhi Rougan Granule Placebo granule
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 282
- Registration Number
- NCT06188611
- Locations
- 🇨🇳
Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung CancerNSCLCPD-1
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT05741021
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 158
- Registration Number
- NCT05740215
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Rulonilimab+LenvatinibDrug: Rulonilimab placebo +Lenvatinib
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 576
- Registration Number
- NCT05408221
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Jinan Central Hospital, Shandong, China
🇨🇳Huizhou Central People's Hospital, Guandong, China
A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis
Phase 3
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 330
- Registration Number
- NCT05305183
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Shandong, China
Study of F527 in Patients With Relapsed or Refractory Lymphoma
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 82
- Registration Number
- NCT05293028
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
Phase 2
- Conditions
- RR DLBCL; PD-1; CD20
- Interventions
- Drug: F520+F007
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 62
- Registration Number
- NCT05178836
Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT05076474
- Locations
- 🇨🇳
Shaohong Yin, Linyi, Shandong, China
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 416
- Registration Number
- NCT05040906
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Linyi, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath